Get the Stockscreener App
1.98
1.00%
-0.02
Pre-market:
2.01
0.03
+1.52%
Inhibikase Therapeutics Inc stock is traded at $1.98, with a volume of 1.23M.
It is down -1.00% in the last 24 hours and up +18.56% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$2.00
Open:
$2.02
24h Volume:
1.23M
Relative Volume:
0.81
Market Cap:
$240.11M
Revenue:
$79,600
Net Income/Loss:
$-47.66M
P/E Ratio:
-3.4712
EPS:
-0.5704
Net Cash Flow:
$-26.07M
1W Performance:
+4.76%
1M Performance:
+18.56%
6M Performance:
+26.92%
1Y Performance:
-12.00%
1-Day Range:
$1.96
$2.055
1-Week Range:
$1.86
$2.055
52-Week Range:
$1.33
$2.58
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.98 | 240.11M | 79,600 | -47.66M | -26.07M | -0.5704 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | Ladenburg Thalmann | Buy |
| Jan-21-26 | Initiated | BofA Securities | Buy |
| Dec-26-25 | Initiated | H.C. Wainwright | Buy |
| Dec-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February - MarketBeat
Aug Ideas: Does Inhibikase Therapeutics Inc stock benefit from AI growth2026 Retail & Low Drawdown Trading Techniques - baoquankhu1.vn
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts - MarketBeat
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by LADENBURG THALM/SH SH - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (IKT) Gains New Coverage with 'Buy' Rati - GuruFocus
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
Ladenburg Thalmann Initiates Inhibikase Therapeutics at Buy - marketscreener.com
Athira Pharma (NASDAQ:LONA) versus Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Analysis - Defense World
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital - Defense World
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4%Still a Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% – Still a Buy? - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Analyzing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock Surge: What’s Driving the 13% Jump Today? - Creative Learning Guild
Inhibikase (IKT) R&D president forfeits 338,282 milestone-based shares - Stock Titan
Inhibikase (IKT) director Amit Munshi forfeits 19,089 milestone-based shares - Stock Titan
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade
Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com
IKT Surges Amid Strategic Developments and Market Shifts - StocksToTrade
Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - timothysykes.com
Certain Warrants of Inhibikase Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2026. - marketscreener.com
ADAR1 group discloses 9.9% Inhibikase (IKT) ownership via shares and warrants - Stock Titan
Fairmount discloses 9.9% Inhibikase (IKT) stake via shares and warrants - Stock Titan
Will Inhibikase Therapeutics Inc. stock deliver consistent dividendsMarket Sentiment Review & Technical Buy Zone Confirmations - mfd.ru
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Does Inhibikase Therapeutics Inc. stock benefit from AI growthChart Signals & Free Expert Approved Momentum Trade Ideas - mfd.ru
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9%Time to Buy? - MarketBeat
Aug Big Picture: Can Inhibikase Therapeutics Inc sustain its profitability2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
What’s next for Inhibikase Therapeutics Inc. stockWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Pfizer (PFE) and Inhibikase Therapeutics (IKT) - The Globe and Mail
Aug Chart Watch: Is Inhibikase Therapeutics Inc a potential multi baggerJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Guidance Update: Is Precision Drilling Corporation affected by consumer sentimentEarnings Overview Summary & Weekly High Potential Alerts - baoquankhu1.vn
Risk Report: Does Inhibikase Therapeutics Inc stock benefit from AI growth2025 Market Outlook & Smart Investment Allocation Insights - baoquankhu1.vn
Market Outlook: Is HCA Healthcare Inc stock a smart retirement pickJuly 2025 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What drives Inhibikase Therapeutics Inc.’s stock priceQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq
BofA Securities initiates coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America - MarketBeat
B of A Securities Initiates Coverage on IKT with 'Buy' Rating | - GuruFocus
BofA Securities initiates coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What analyst consensus says on Inhibikase Therapeutics Inc. stockQuarterly Profit Report & Expert Curated Trade Ideas - Bollywood Helpline
Can Inhibikase Therapeutics Inc. stock sustain free cash flow growthMarket Growth Report & Daily Stock Momentum Reports - bollywoodhelpline.com
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):